Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Thymus Neoplasms, lymphatic system disorder, mixed neoplasm, neoplasm, thymic epithelial neoplasm, thymoma	Recruiting	Phase 1 / Phase 2	2026-05-20		NCT07598955

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Biotech	32

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Peking University Shenzhen Hospital	Shenzhen	China	68

Clinical trials